SOURCE: Implant Sciences

Implant Sciences

July 13, 2011 07:00 ET

Implant Sciences Files New Patent Application on Method for Reducing False Alarms in Explosives Trace Detection

Method to Reduce False Alarms; Fortifies Company's Portfolio of 12 Patents

WILMINGTON, MA--(Marketwire - Jul 13, 2011) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced it has filed a new patent application with the US Patent and Trademark Office. The patent application, "Chemical Analysis Using Hyphenated Low and High Field Ion Mobility," is one of several pending for Implant Sciences. The Company's trace detection intellectual property portfolio also includes 12 issued patents with two more under license.

Implant Sciences presented the scientific discovery covered by the new patent application at the 3rd Annual Trace Explosives Detection Workshop in Portland, Oregon. The presentation titled "Accurate Explosives Detection and Identification Using Orthogonal Techniques" demonstrated an advanced technique for improving accuracy in identifying trace levels of explosives.

"As the number and type of threats continues to grow, it is critical that new solutions be developed to quickly and accurately identify explosives with low false alarm rates," stated Todd Silvestri, Implant Sciences' Vice President of Technology. "The integration of our current ion mobility spectrometer with an advanced differential mobility spectrometer will significantly improve the ability of the system to discriminate between dangerous and benign substances beyond the current capabilities of systems in use today."

Glenn D. Bolduc, President and CEO added, "This invention continues the Implant Sciences tradition of innovation exemplified by our non-radioactive ion generation, automatic self-calibration, and non-contact sampling technologies. The ability of our technology team to solve the problems faced daily by security professionals is why our products enjoy growing acceptance around the world."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 Portable Explosives Detector has been designated as Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact